Cardiol Therapeutics Inc.

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

18

Website

www.cardiolrx.com

Country

Canada

Exchange

Toronto

Oakville, Canada

Cardiol Therapeutics Inc., a clinical-stage life sciences company develops anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis for the treatment of recurrent pericarditis.

The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Incorporated in 2017, Cardiol Therapeutics is headquartered in Oakville, Canada.

Key Stats

52-Week Range

C$1.23C$2.33

Beta0.51

Trailing P/EN/A

Forward P/E-6.07

Trailing EPS-0.39

Avg Volume

Earnings & Analyst

Next Earnings2026-08-13

EPS Estimate-0.10

Target Mean PriceC$6.00

RecommendationStrong Buy

Recommendation Mean1.40

Recent SEC Filings

SEC filings for this ticker are not available yet.